Search results

Jump to navigation Jump to search
  • ...y in sufficient amounts to trigger specific immunoglobulin production; the antigen is introduced in a form that has been rendered relatively harmless. ...sponse is defined as the interaction between [[antibody|antibodies]] and [[antigen]]s. Antibodies are specific proteins released from a certain class of immun
    9 KB (1,304 words) - 08:42, 30 May 2009
  • ...The '''classic cascade''' is C1 and its subcomponents, which recognize an antigen on a cell wall, which triggers the "complement cascade". ...h complement factor B binding to a cell surface, rather than to a specific antigen. This is the '''alternative''' or '''properdin''' pathway, which depends on
    4 KB (608 words) - 06:10, 31 May 2009
  • Screen with annual [[CA-125 antigen]] and transvaginal [[ultrasonography]] does not reduce mortality according Recommendations for the use of the CA-125 antigen in monitoring extent of cancer after treatment have been made by the [http:
    4 KB (556 words) - 21:28, 19 June 2014
  • ...orescence intensity for each 'CD' clusters of differentiation marker. The antigen distribution for thousands of cells is printed in graphical histograms whic
    5 KB (704 words) - 10:07, 4 March 2013
  • ...obe). Then, the probe that was labeled with either radio-, fluorescent- or antigen-labeled bases is localized and quantitated in the tissue using either [[Aut
    2 KB (313 words) - 20:47, 18 July 2010
  • {{r|Antigen}}
    3 KB (378 words) - 14:00, 21 June 2024
  • ;Anti-MS4A1 (CD20 antigen) * [[Alemtuzumab]] is a "a therapeutic antibody directed against the CDw52 antigen ([http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=CAI15846 Entrez
    10 KB (1,356 words) - 06:07, 5 April 2024
  • ...t enhancer elements that are found in the bf1-1 promoter. The EBV nuclear antigen 2 also upregulates bf1-1, which requires CBF1 for its trans-activation. CB ...://jvi.asm.org/cgi/content/abstract/80/16/8133 "Epstein-Barr Virus Nuclear Antigen 2 trans-Activates the Cellular Antiapoptotic bfl-1 Gene by a CBF1/RBPJ-Depe
    5 KB (712 words) - 22:32, 14 February 2010
  • | vaccine/antigen | [[vaccine]], [[antigen]]
    6 KB (792 words) - 21:21, 12 December 2008
  • ...challenging antigen due to the release of [[histamine]] which follows the antigen-antibody reaction and causes smooth muscle contraction and increased vascul ...]] is an allergic reaction provoked by re-exposure to a specific type of [[antigen]] referred to as an allergen. Exposure may be by ingestion, inhalation, in
    8 KB (1,120 words) - 02:34, 25 June 2010
  • ...> [[monoclonal antibody]] consisting of humanized [[murine]] antibody with antigen-binding, complementary-determining regions from murine VEGF".<ref>{{MeSH|Be
    3 KB (376 words) - 14:53, 17 July 2010
  • ...ecognition of antigens, and the [[major histocompatibility complex]] (MHC) antigen system. Of these, the first two are inherently variable and susceptible to ...ities with certain host antigens; thus, any antibody produced against this antigen (which mimics the self-antigens) can also, in theory, bind to the host anti
    12 KB (1,683 words) - 12:37, 25 June 2010
  • ...view=long&pmid=10644276 |issn=}}</ref> [[complement C1 inhibitor protein]] antigen is low in type I and normal in type II.
    3 KB (417 words) - 13:05, 28 March 2011
  • {{r|Antigen}}
    4 KB (483 words) - 14:44, 23 June 2024
  • ...eloid cells are believed to have differentiated as a result of prolonged [[antigen|antigenic]] stimulation. Further differentiation or fusion of epithelioid c
    4 KB (490 words) - 21:31, 17 February 2010
  • ...cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst 2009 Aug 31; [e-pub ahead of pri
    8 KB (1,174 words) - 07:48, 28 August 2013
  • ...atin]]; E: immunohistochemistry showing staining for [[Epithelial membrane antigen|EMA]]; F: immunohistochemistry showing staining for [[Vimentin]]. Scale: Pa
    4 KB (539 words) - 08:08, 17 May 2010
  • ...[[rheumatoid factor]], [[antinuclear factor]] (ANF), [[extractable nuclear antigen]] and specific antibodies.
    4 KB (565 words) - 08:50, 24 June 2023
  • # An [[immunoadsorbent]] consisting of a solid matrix to which the antigen is coupled to is prepared. ...the serum over the adsorbent. Antibodies in the mixture specific for the antigen will bind and be retained, while antibodies of other specificities and prot
    17 KB (2,435 words) - 22:09, 18 December 2010
  • ...tigen presentation in infected cells. If an infected cell can't present an antigen, then the body does not know that it is infected, and will not provide immu ...it can cause infection in the host. CMV has genes that interfere with the antigen presentation of infected cells, thus limiting the immune response to it. Th
    21 KB (3,267 words) - 20:07, 1 November 2013
View ( | ) (20 | 50 | 100 | 250 | 500)